Abstracts tagged "giant cell arteritis"

Abstract Number: 0412 • ACR Convergence 2020
2019 Novel Coronavirus Disease (COVID-19) in Patients with Large-Vessels Vasculitis: Single-centre Experience in Paris
Chloé Comarmond¹, Mathilde Leclercq¹, Gaëlle Leroux², Cindy Marques², Alexandre Le Joncour³, Fanny Domont², Céline Hatte¹, Ségolène Toquet¹, Perrine Guillaume-Jugnot¹, Anne-Claire Desbois¹, Mathieu Vautier¹, Aude Rigolet¹, Yves Allenbach⁴, Olivier Benveniste⁵, David Saadoun² and Patrice Cacoub², ¹Assistance Publique des Hopitaux de Paris, Paris, France, ²AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, Paris, France, ³APHP, paris, France, ⁴Sorbonne Université, Paris, Ile-de-France, France, ⁵Sorbonne Université, paris, France
Background/Purpose: Advanced age and cardiovascular diseases are recognized as major comorbidities associated with severe forms of coronavirus disease 2019 (COVID-19) caused by the severe acute…
Abstract Number: 1918 • ACR Convergence 2020
Efficacy and Safety of Methotrexate in Giant Cell Arteritis: Results from a Bicentric Portuguese Cohort Study
Sofia Barreira¹, Ana Rita Cruz-Machado², Eduardo Dourado³, Joana Martinho², Diana Raimundo⁴, Luísa Brites⁵, Helena Assunção⁵, Vítor Teixeira⁶, Nikita Khmelinskii², Carla Macieira², José A. P. da Silva⁷, João Eurico Fonseca⁸ and Cristina Ponte², ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, ²Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ³Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Lisboa, Portugal, ⁴Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal, ⁵Rheumatology Department, Centro Hospitalar Universitário Coimbra, Coimbra, Portugal, ⁶Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ⁷9.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, ⁸Instituto de Medicina Molecular, Faculdade Medicina Universidade de Lisboa and Centro Hospitalar Universitário Lisboa Norte., Lisboa, Portugal
Background/Purpose: Giant Cell Arteritis (GCA) is a large- and medium-sized vessel vasculitis affecting patients >50 years-old. High-doses of glucocorticoids (GCs) should be initiated promptly to…
Abstract Number: 1937 • ACR Convergence 2020
Aortic Aneurysm in Giant Cell Arteritis: A Nationwide Analysis
Jiayi Zheng¹, Ruoning Ni², Yan Tang³ and Liangjing Lu⁴, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China (People's Republic), ²St. Agnes Hospital, Baltimore, MD, ³Department of Stomatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China (People's Republic), ⁴Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: Giant cell arteritis (GCA) is an inflammatory vasculopathy affecting primarily medium and large sized arteries. Previous studies have demonstrated a higher prevalence of aortic…
Abstract Number: 0418 • ACR Convergence 2020
Prevalence of Thyroid Disease Among Patients with Vasculitis
Tanaz Kermani¹, David Cuthbertson², Simon Carette³, Nader Khalidi⁴, Curry L. Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Antoine Sreih¹³, Kenneth Warrington¹² and Peter Merkel¹³, ¹David Geffen School of Medicine / University of California, Los Angeles, CA, ²University of South Florida, Tampa, ³Division of Rheumatology, Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Utah, Salt Lake City, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, ⁸Brigham and Women's, Boston, ⁹University of Pittsburgh, Denver, CO, ¹⁰Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Previous studies have reported higher risk of thyroid disease in patients with giant cell arteritis (GCA) and ANCA-associated vasculitis (AAV) compared to age- and…
Abstract Number: 1919 • ACR Convergence 2020
Efficacy & Safety of Tocilizumab in Giant Cell Arteritis: A Single Centre NHS Experience Using Imaging (Ultrasound and PET CT) as a Diagnostic and Monitoring Tool
Alwin Sebastian¹, Abdul Kayani¹, Diana Prieto-Peña², Alessandro Tomelleri³, Madeline Whitlock¹, Kornelis S. M. van der Geest⁴ and Bhaskar Dasgupta¹, ¹Rheumatology, Mid and South Essex University Hospital NHS Foundation Trust, Southend University Hospital, United Kingdom, Westcliff on sea, England, United Kingdom, ²Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, Milan, Italy, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, Netherlands, Groningen, Netherlands
Background/Purpose: Tocilizumab (TCZ), an IL-6 receptor blocker is approved to treat relapsing, refractory Giant cell arteritis (GCA) We here report our real-life clinical experience with…
Abstract Number: 1938 • ACR Convergence 2020
Risk for Vision Loss and Relapse in Patients with Giant Cell Arteritis
Anne Bull Haaversen¹ and Andreas Diamantopoulos², ¹Martina Hansens Hospital, Hosle, Norway, ²Martina Hansens Hospital, Baerum, Norway
Background/Purpose: Giant cell arteritis (GCA) involves both the cranial and large vessels. Studies have shown that while the vision loss rates are higher, the relapse…
Abstract Number: 0420 • ACR Convergence 2020
Prospective Analysis of the Prevalence of Giant Cell Arteritis in Consecutive Newly Diagnosed Patients with Polymyalgia Rheumatica
Lara Burg¹, Peter Brossart², Charlotte Behning³ and Valentin Schaefer⁴, ¹Clinic for Internal Medicine III, Department of Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ²Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ³Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ⁴Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Giant cell arteritis (GCA) is the most common form of systemic vasculitis affecting people aged 50 years and older.1 Although it is known, that…
Abstract Number: 1920 • ACR Convergence 2020
Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis and Visual Impairment
Andrea Rubbert Roth¹, Scott Tschuppert², Thomas Neumann², Ulf Benecke³, Ian Pirker³ and Johannes von Kempis³, ¹Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, ²Kantonsspital St Gallen, St.Gallen, Switzerland, ³Kantonspital St Gallen, St. Gallen, Switzerland
Background/Purpose: Tocilizumab (TCZ) represents a potent new therapeutic principle for patients with GCA, however, data on efficacy and safety in patients who present with visual…
Abstract Number: 1939 • ACR Convergence 2020
Definitions and Reliability Assessment of Chronic Ultrasound Lesions of the Axillary Artery in Giant Cell Arteritis: A Study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group
Valentin Schaefer¹, Stavros Chrysidis², Greta Carrara³, Wolfgang Schmidt⁴, George A. Bruyn⁵, Bhaskar Dasgupta⁶, Eugenio De Miguel⁷, Andreas Diamantopoulos⁸, Christina Duftner⁹, Ulrich Fredberg¹⁰, Berit Nielsen¹¹, Wolfgang Hartung¹², Alojzija Hocevar¹³, Annamaria Iagnocco¹⁴, Aaron Juche⁴, Tanaz Kermani¹⁵, Tove Lorenzen¹⁶, Pierluigi Macchioni¹⁷, Marcin Milchert¹⁸, Uffe Døhn¹⁹, Sara Monti²⁰, Chetan Mukhtyar²¹, Cristina Ponte²², Carlo Scire²³, Lene Terslev²⁴, Luca Seitz²⁵ and Christian Dejaco²⁶, ¹Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ²Sydvestjysk Sygehus Esbjerg, Esbjerg, Denmark, ³Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy, ⁴Immanuel Krankenhaus Berlin Buch, Berlin, Germany, ⁵Rheumatology, Reumakliniek Lelystad, Lelystad, Netherlands, ⁶Rheumatology, Mid and South Essex University Hospital NHS Foundation Trust, Southend University Hospital, United Kingdom, Westcliff on sea, England, United Kingdom, ⁷Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁸Martina Hansens Hospital, Baerum, Norway, ⁹Medical University Innsbruck, Innsbruck, Austria, ¹⁰Silkeborg Regional Hospital, Silkeborg, Denmark, ¹¹Aarhus University Hospital, Aarhus, Denmark, ¹²Asklepios Klinik Bad Abbach, Bad Abbacg, Germany, ¹³University Medical Center, Rheumatology, Ljubljana, LJUBLJANA, Slovenia, ¹⁴Università degli Studi di Torino, Academic Rheumatology Centre, Turin, Italy, ¹⁵David Geffen School of Medicine / University of California, Los Angeles, CA, ¹⁶Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ¹⁷Unità Operativa di Reumatologia/Arcispedale S. Maria Nuova, Reggio Emilia, Italy, ¹⁸Pomeranian Medical University, Szczecin, Poland, ¹⁹Center for Rheumatology and Spine Diseasesand COPECARE, Copenhagen, Denmark, ²⁰Fondazione IRCCS Policlinico S Matteo, University of Pavia, Pavia, Italy, ²¹Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom, ²²Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ²³University of Ferrara, Ferrara, Italy, ²⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup., Copenhagen, Denmark, ²⁵Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ²⁶South Tyrol Health Trust, Hospital of Bruneck, Bruneck, Italy
Background/Purpose: The OMERACT Ultrasound (US) large vessel vasculitis task force has recently defined the US appearance of normal axillary arteries (AA) and the key elementary…
Abstract Number: 0510 • ACR Convergence 2020
Expression and Functional Activity of the Angiotensin II System in Temporal Artery Lesions from Patients with Giant Cell Arteritis
Marco A. Alba¹, Ester Planas-Rigol², Marc Corbera-Bellalta², Nekane Terrades-García³, Ana García-Martínez³, Sergio Prieto-González¹, Roser Alba-Rovira³, Georgina Espígol-Frigolé¹, Javier Marco-Hernández¹, Jose Hernández-Rodríguez¹, Josep M Grau⁴ and Maria C. Cid¹, ¹Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, IRB-CELLEX. Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain, Barcelona, Spain, ³Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, IRB-CELLEX. Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain, Barcelona, ⁴Department of Internal Medicine, Hospital Clínic and Fundació Cellex, University of Barcelona, Barcelona, Spain., Barcelona
Background/Purpose: Giant cell arteritis (GCA) is a large and medium size-vessel granulomatous vasculitis that predominantly affects the aorta and its major branches. The renin-angiotensin-aldosterone system…
Abstract Number: 1922 • ACR Convergence 2020
Association of Leukocyte Populations in Peripheral Blood and Arterial Wall Inflammation Assessed by FDG-PET in Takayasu’s Arteritis and Giant Cell Arteritis
K. Bates Gribbons¹, Kaitlin Quinn², Mark Ahlman³, Peter Merkel⁴ and Peter C. Grayson⁵, ¹McGovern Medical School UT Houston, Houston, TX, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Positron emission tomography (PET) is useful to demonstrate fluorodeoxyglucose (FDG) uptake in the large arteries in both Takayasu’s arteritis (TAK) and giant cell arteritis…
Abstract Number: 1940 • ACR Convergence 2020
In Newly Diagnosed Giant Cell Arteritis in a Real Life Setting Relapses Are Seen in More Than a Third of Patients – and Despite Faster Early Reduction High Cumulative Glucocorticoid Doses Are Reached
Laura Felten¹, Nicolai Leuchten¹ and Martin Aringer², ¹University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, Dresden, Germany
Background/Purpose: To investigate real life glucocorticoid (GC) dosing and relapse rates in patients with new onset giant cell arteritis (GCA) in a single center.Methods: Complete…
Abstract Number: 0513 • ACR Convergence 2020
Mass Spectrometry Identifies Novel Biomarkers in Giant Cell Arteritis, Useful in Patients on Interleukin-6 Receptor Blockade
Sebastian Unizony¹, Robert Morris², Johannes Kreuzer², Wilhelm Haas² and John H. Stone¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA
Background/Purpose: We aimed to identify biomarkers of disease activity in giant cell arteritis (GCA) patients treated with prednisone monotherapy and with prednisone in combination with…
Abstract Number: 1923 • ACR Convergence 2020
Angiographic Progression of Disease in Large-Vessel Vasculitis
Kaitlin Quinn¹, Himanshu Dashora², Mark Ahlman³, Elaine Novakovich² and Peter C. Grayson², ¹Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD
Background/Purpose: Angiography is essential to detect vascular disease in patients with large-vessel vasculitis (LVV). Guidelines differ on the role of periodic angiography to monitor patients…
Abstract Number: 1941 • ACR Convergence 2020
Outcome of Giant Cell Arteritis Patients Who Were Primarily Admitted for Venous Thromboembolism Events
Shu Cao¹, Caroline Bresnan², Si Li³, Yichen Wang³ and Yih Chang Lin¹, ¹University of South Florida, Morsani College of Medicine, Tampa, FL, ²University of South Florida, Morsani College of Medicine, Tampa, ³The Wright Center for Graduate Medical Education, Scranton
Background/Purpose: Giant cell arteritis (GCA) has been shown to have an increased risk of developing deep venous thrombosis (DVT), pulmonary embolism (PE) and combined thromboembolism…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].